Navigation Links
New mouse collaborative cross resource promises new cures and treatments for diseases

A new genetic resource from an international research consortium is expected to accelerate the development of new cures and treatments for a wide range of human diseases. This project, called the mouse "Collaborative Cross" (CC) resource, will increase the likelihood that experiments conducted in mice will advance our understanding of human biology. The mice in the CC have 90 percent of the genetic diversity present in laboratory mice, which mirrors the genetic diversity in humans. This will enable researchers to study traits and human diseases of complex origins in an appropriate model system.

Key findings arising from the CC will be published in February 2012 as a series of articles across both scientific journals published by the Genetics Society of America (GSA): GENETICS and G3: Genes|Genomes|Genetics. The 15 articles highlight the contributions of the CCand a companion mouse resource called the "Diversity Outbred" (DO) resourceto a number of important areas of human health. The MCC and DO are already shedding light on the genes influencing HDL cholesterol levels, systolic blood pressure, triglyceride levels, glucose, and variation in hematological traits like red and white blood cell counts, reactions to the influenza A virus, and mouse brain reaction to clozapine, a drug used for schizophrenia.

According to Dr. Fernando Pardo-Manuel de Villena (University of North Carolina at Chapel Hill Department of Genetics and Lineberger Comprehensive Cancer Center), one of the primary leaders of the CC, "A common complaint about using animal models has been the fact that some research doesn't carry over when applied to humans. The Collaborative Cross resource hopes to answer this complaint."

"Genetic causes may underlie many idiosyncratic adverse drug reactions," explained Dr. Gary Churchill (The Jackson Laboratory), another leader of the CC project. "Initial screening with this genetically diverse and heterogeneous model may allow for more realistic assessments of the risk of adverse effects and may be a reliable route for applying findings from mouse to human populations."

Dr. David Threadgill (North Carolina State University and UNC Lineberger), who originally proposed the idea for this resource and is also a leader of the project, added, "Research on mouse models may lead to increased safety in human drug trials and consequently has the potential of reducing the costs of drug development."

"Publishing these papers in GSA's sister journals enables those interested in this research to access a large body of information quickly and easily," said Dr. Lauren McIntyre, senior editor of the journal GENETICS and professor in the Department of Molecular Genetics and Microbiology at the University of Florida. "The journals have made all the data associated with the papers openly available, and are committed to the widest possible distribution. This group of research articles should help accelerate the development of new treatments and drugs."

The international consortium developing these mouse populations includes the University of North Carolina (UNC), North Carolina State University (NCSU), The Jackson Laboratory, Tel Aviv University, Oxford University and Geniad/Australia. The mice are housed and 'curated' at UNC-Chapel Hill. The CC and DO populations are available for researchers worldwide who need a common genetic reference population for the integrative analysis of complex systems.

Contact: Phyllis Edelman
Genetics Society of America

Related biology news :

1. Sharp images from the living mouse brain
2. Multiple births lead to weight gain and other problems for mouse moms and male offspring
3. Severe congenital disorder successfully treated in a mouse model for the first time
4. Cleft lip corrected genetically in mouse model
5. Self-organized pituitary-like tissue from mouse ES cells
6. UCLA Engineering researchers help develop complete map of mouse genetic variation
7. Mouse genome sequences reveal variability, complex evolutionary history
8. A mouse model brings new perspectives on Lafora disease
9. Mouse virus erroneously linked to chronic fatigue syndrome, UCSF collaborative study finds
10. Of mice and men: UNC-led team solves mouse genome dilemma
11. What is a laboratory mouse? Jackson, UNC researchers reveal the details
Post Your Comments:
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... Oct. 27, 2015 In the present market ... concern for various industry verticals such as banking, healthcare, ... the growing demand for secure & simplified access control ... such as hacking of bank accounts, misuse of users, ... such as PC,s, laptops, and smartphones are expected to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... -- 2 nouvelles études permettent d , ... entre les souches bactériennes retrouvées dans la plaque ... . Ces recherches  ouvrent une nouvelle voie ... efficace de l,un des problèmes de santé les ...    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
Breaking Biology Technology: